Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Nexavar Prescribers: Oncologists

Analysis of: Positive Results Prompt US National Cancer Institute To Make Gleevec(R) Available To Patients In Post-Surgical GIST Study (www.medicalnewstoday.com)
The primary end point of the phase III trial "Imatinib Mesylate (Gleevec) in Treating Patients with Primary GIST that has been Completely Removed by Surgery" was recurrence free survival with the secondary endpoints of overall survival, efficacy, and safety. The study was closed early with the announcement...
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
Analysis of: ImClone's Erbitux Fails Study in Pancreatic Cancer (www.bloomberg.com)
Erbitux plus gemcitabine failed to improve the results in pancreatic cancer therapy.Other biologics have also failed due to practical reasons.
Eric Whitman, MD, Medical Director, Office of Grants and Research
Eric Whitman, MD, Medical Director, Office of Grants and Research
Atlantic Health System Inc
Analysis of: Cosmetic surgeons aim lasers to melt away fat (www.bucyrustelegraphforum.com)
This article describes a new way of performing liposuction, or cosmetic removal of "extra" fat cells, using a laser device instead of the traditional suction device.
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
Analysis of: Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa™ in Brain Cancer (www.myriad.com)
GBMs most common primary brain tumor adultsLack of efficacy with treatment options makes new treatments attractive Azixa will improve on present treatments
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
Analysis of: Neoprobe Announces Interim Phase 2 Lymphoseek Results (www.pipelinereview.com)
There are two major indications for SN mappingThe indications are melanoma and breast cancerThere is a need to improve the vehicle used to carry out SN mapping
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
Analysis of: Drug Industry Increasingly Influences Breast Cancer Research (pharmalive.com)
Breast cancer gets a disproportionate funding in drug development.Other diseases get less drug money funding than breast cancer.Some get even more funding than breast cancer
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
Analysis of: Genta Cites Publication of Study Showing Improved Outcomes in CLL Patients Treated With Genasense Plus Chemotherapy (pharmalive.com)
CLL is a form of leukemia where BCL 2 inhibition will impact Genasense represents a novel therapeutic approach with promise.
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
Analysis of: Bayer to File for Nexavar Approval for Liver Cancer (www.therapeuticsdaily.com)
Nexavar has demonstrated response in HCC.HCC is a disease with few treatment options in advanced stage.Most HCC patients become advanced stage patients.While in US HCC relatively uncommmon cancer, one of the most common around the world.
Analysis of: Bayer to File for Nexavar Approval for Liver Cancer (www.therapeuticsdaily.com)
Nexavar continues to expand its place in the oncology arena.Nexavar is approved for renal cell ca and I suspect hepatocellular approval is not far behind.
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
Analysis of: Targeted Drugs, Vaccines Among Cancer Advances in 2006 (www.cancer.org)
Targeted cancer therapy is a revolution in treatment. Targeted therapy will take over from non targeted chemo. Some drugs are more targeted than others.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next91 to 100 of 126

Analytics


Generated at 2009-01-07T19:00:58.307